AKTX Akari Therapeutics, Plc Stock Quote

AKTX [NASD]

Healthcare | Biotechnology | United Kingdom

Index	-	P/E	-	EPS (ttm)	-0.73	Insider Own	26.88%	Shs Outstand	33.87M	Perf Week	15.75%
Market Cap	90.05M	Forward P/E	-	EPS next Y	-0.01	Insider Trans	0.00%	Shs Float	18.75M	Perf Month	58.92%
Income	-18.10M	PEG	-	EPS next Q	-	Inst Own	20.80%	Short Float	0.92%	Perf Quarter	80.37%
Sales	-	P/S	-	EPS this Y	12.60%	Inst Trans	0.74%	Short Ratio	0.68	Perf Half Y	47.00%
Book/sh	0.14	P/B	21.00	EPS next Y	0.00%	ROA	-161.50%	Target Price	-	Perf Year	57.22%
Cash/sh	0.40	P/C	7.32	EPS next 5Y	-	ROE	-880.40%	52W Range	0.87 - 3.76	Perf YTD	58.92%
Dividend	-	P/FCF	-	EPS past 5Y	16.30%	ROI	-	52W High	-21.81%	Beta	1.56
Dividend %	-	Quick Ratio	1.50	Sales past 5Y	-	Gross Margin	-	52W Low	237.93%	ATR	0.29
Employees	10	Current Ratio	1.50	Sales Q/Q	-	Oper. Margin	-	RSI (14)	67.55	Volatility	20.05% 10.45%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	133.10%	Profit Margin	-	Rel Volume	1.08	Prev Close	2.93
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Dec 11 BMO	Payout	-	Avg Volume	251.98K	Price	2.94
Recom	2.00	SMA20	32.49%	SMA50	53.10%	SMA200	56.58%	Volume	272,544	Change	0.34%

Jan-04-19

Upgrade

B. Riley FBR

Neutral → Buy

$2.50 → $3

Feb-08-18

Initiated

B. Riley FBR, Inc.

Neutral

Sep-22-17

Upgrade

William Blair

Mkt Perform → Outperform

May-31-17

Upgrade

Chardan Capital Markets

Sell → Neutral

Apr-17-17

Reiterated

Chardan Capital Markets

Sell

$6.50 → $5

Jul-11-16

Initiated

Chardan Capital Markets

Sell

Jan-06-21 09:32AM	Akari Therapeutics to Participate in Two January Virtual Investor Conferences GlobeNewswire
Dec-11-20 09:00AM	Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress GlobeNewswire +5.26%
08:55AM	Akari Therapeutics Announces New Clinical Data that Show Long-Term Self-Administered Nomacopan is Well-Tolerated and Substantially Reduces Transfusion Dependence in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) GlobeNewswire
Dec-03-20 10:00AM	Akari Therapeutics Announces Publication in American Journal of Pathology Highlighting Potential of Nomacopan in Treatment of Uveitis and Retinal Disease GlobeNewswire +14.11%
Nov-30-20 11:35PM	Akari Therapeutics (NASDAQ:AKTX) Will Have To Spend Its Cash Wisely Simply Wall St.
Oct-27-20 09:00AM	Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy of Dermatology and Venereology (EADV) Virtual Congress October 29 GlobeNewswire
Oct-06-20 08:30AM	Akari Therapeutics Announces Further Clinical Trial Progress Using Nomacopan to Treat COVID-19 Pneumonia GlobeNewswire +6.94%
Sep-29-20 09:30AM	Akari Therapeutics to Present Its Phase III Plans at the International Pemphigus & Pemphigoid Foundation (IPPF) Patient Education Conference GlobeNewswire
Sep-10-20 08:00AM	Akari Therapeutics to Participate in Two September Virtual Investor Conferences GlobeNewswire +5.70%
Sep-02-20 06:19AM	Have Insiders Been Buying Akari Therapeutics, Plc (NASDAQ:AKTX) Shares? Simply Wall St.
Sep-01-20 08:30AM	Akari Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Recent Clinical Progress GlobeNewswire
Aug-31-20 07:00AM	Akari Therapeutics Announces International Clinical Development Program of Nomacopan for the Potential Treatment of COVID-19 Pneumonia GlobeNewswire
Aug-12-20 08:23AM	Akari Therapeutics Announces Successful End-of-Phase II Meeting With FDA to Initiate Pivotal Phase III Study for Treatment of Bullous Pemphigoid With Nomacopan GlobeNewswire
Jul-01-20 09:16AM	Akari Therapeutics Enters into a Securities Purchase Agreement for up to $30 Million with Aspire Capital Fund, LLC GlobeNewswire +8.72%
09:15AM	Akari Therapeutics Announces Appointment of Chief Financial Officer GlobeNewswire
Jun-25-20 11:23AM	3 Biotech Stocks Under $5 With 100%-Plus Upside Potential TipRanks
May-29-20 07:00AM	Akari Therapeutics Reports First Quarter 2020 Financial Results and Highlights Recent Clinical Progress GlobeNewswire
May-21-20 11:32AM	Akari Therapeutics Receives Positive EMA Opinion on Orphan Designation for Nomacopan for Bullous Pemphigoid GlobeNewswire
May-04-20 07:30AM	Akari Therapeutics to Participate in STRH Life Sciences Virtual Meeting Series GlobeNewswire
May-01-20 07:00AM	Akari Therapeutics Announces Positive Topline Results from Fully Recruited Phase II Study of Nomacopan in Bullous Pemphigoid Patients GlobeNewswire
Mar-31-20 08:00AM	Akari Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights GlobeNewswire -5.84%
Mar-04-20 08:52AM	Akari Therapeutics, Plc Announces Closing of $9.5 Million Private Placement GlobeNewswire
Feb-21-20 07:46AM	The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion Benzinga
Feb-20-20 05:34PM	Akari Therapeutics, Plc Announces Private Placement GlobeNewswire
Jan-27-20 08:58AM	Akari Therapeutics Announces Preclinical Ophthalmic Data Showing Nomacopan Reduces Both Vascular Endothelial Growth Factor (VEGF) and Retinal Inflammation Supporting Nomacopan as a Potential Treatment Option for Back-of-the-Eye Diseases GlobeNewswire
Jan-10-20 09:30AM	Akari Therapeutics Announces Positive Interim Data from Phase III Paroxysmal Nocturnal Hemoglobinuria (PNH) Study GlobeNewswire +24.86%
Dec-23-19 08:45AM	Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) Following the Opening of its IND GlobeNewswire
Dec-02-19 08:30AM	Akari Therapeutics Announces Pivotal Phase III Trial Design of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA), Following FDA Meeting GlobeNewswire
Nov-18-19 06:09AM	What Kind Of Shareholder Owns Most Akari Therapeutics, Plc (NASDAQ:AKTX) Stock? Simply Wall St.
Nov-04-19 08:33AM	Akari Therapeutics Reports Third Quarter 2019 Financial Results And Highlights Recent Clinical Progress GlobeNewswire
Oct-14-19 08:37AM	Akari Therapeutics Announces New Data from Atopic Keratoconjunctivitis (AKC) Patients Supporting the Potentially Beneficial Role of Nomacopan as an Inhibitor of both C5 and LTB4 in the Ongoing Phase I/II AKC Trial GlobeNewswire
Oct-10-19 08:45AM	Akari Therapeutics Announces Positive Phase II Clinical Data in Orphan Blistering Skin Disease Bullous Pemphigoid at the 28th EADV Congress GlobeNewswire -12.44%
07:31AM	The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO Benzinga
Oct-06-19 05:15PM	The Week Ahead In Biotech: Pfenex And Clinuvel On The Radar Ahead of FDA Decisions, 2 IPOs On Deck Benzinga
Sep-19-19 06:54AM	How Much Cash Is Left In The Bank For Akari Therapeutics, Plc (NASDAQ:AKTX)? Simply Wall St.
Sep-18-19 08:00AM	Akari Therapeutics to Participate in Ladenburg Thalmann Healthcare Conference GlobeNewswire
Sep-16-19 10:29AM	Akari's Nomacopan Gets Orphan Drug Tag for Rare Skin Disease Zacks
Sep-13-19 08:00AM	Akari Therapeutics Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid GlobeNewswire
Sep-04-19 10:02AM	Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More Zacks
Sep-03-19 07:00AM	Akari Therapeutics to Participate in Citi and H.C. Wainwright Conferences in Early September GlobeNewswire -8.17%
Sep-02-19 09:17AM	Akari's Nomacopan Gets Orphan Drug Tag for Rare Disease Zacks
Aug-30-19 12:51PM	A Look At Benzinga Pro's Most-Searched Tickers For August 30, 2019 Benzinga +7.77%
11:39AM	The Daily Biotech Pulse: Genmab-Novartis Multiple Sclerosis Drug Aces Late-Stage Studies, Akari Nets Orphan Drug Designation Benzinga
10:54AM	Akari's 2-Day Rally: What You Need To Know Benzinga
07:27AM	Akari Therapeutics shares soar 13% premarket after FDA grants Orphan Drug designation to nomacopan MarketWatch
07:00AM	Akari Therapeutics Nomacopan Granted U.S. Orphan Drug Designation for Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy (HSCT-TMA) GlobeNewswire
Aug-29-19 08:06AM	Akari Therapeutics Reports Second Quarter 2019 Financial Results And Highlights Recent Clinical Progress GlobeNewswire +12.21%
Aug-15-19 11:55AM	A Look At Benzinga Pro's Most-Searched Tickers For August 15, 2019 Benzinga -29.79%
Aug-14-19 12:27PM	Biopharma News: Why Akari Therapeutics (AKTX) Stock Is Soaring Today InvestorPlace +62.22%
08:58AM	Akari Therapeutics' stock rockets on heavy volume after FDA grants nomacopan 'Fast Track' designation MarketWatch
08:00AM	Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) GlobeNewswire
Aug-09-19 08:30AM	Akari Therapeutics announces new data demonstrating synergistic benefits of nomacopans bifunctional C5 and LTB4 inhibitory activity in pemphigoid disease GlobeNewswire
Jul-31-19 09:57AM	Akari Therapeutics Announces Oral Presentation of Nomacopan Phase II Data in Patients with Bullous Pemphigoid at the 28th European Academy of Dermatology and Venereology (EADV) Congress, October 9-13, 2019 GlobeNewswire
Jul-17-19 03:00PM	Before You Buy Akari Therapeutics, Plc (NASDAQ:AKTX), Consider Its Volatility Simply Wall St.
Jul-04-19 08:35AM	Alexion's Ultomiris Receives EU Approval for PNH in Adults Zacks
Jun-28-19 09:22AM	Akari Therapeutics, Plc Announces $4.5 Million Registered Direct Offering GlobeNewswire
08:45AM	Alexion Receives FDA Approval for Label Expansion of Soliris Zacks
Jun-21-19 11:05AM	Alexion's sBLA for Ultomiris Gets Priority Review From FDA Zacks
Jun-20-19 09:35AM	Akari (AKTX) Eye Candidate Proves Safety in Early-Stage Study Zacks -5.48%
Jun-19-19 11:24AM	Akari's Lead Candidate Found Safe, Effective In Treating Eye Inflammation Benzinga
07:39AM	Akari Therapeutics Nomacopan Demonstrates Positive Early Safety and Efficacy in Phase I/II Clinical Study in Moderate-to-Severe Atopic Keraconjunctivitis (AKC) GlobeNewswire
May-29-19 07:45AM	Akari Therapeutics Reports First Quarter 2019 Financial Results And Highlights Recent Clinical Progress GlobeNewswire -7.46%
Apr-29-19 07:30AM	FDA Events Put Healthcare Stocks In The Headlines: Here's One That No One's Talking About Yet ACCESSWIRE
Apr-26-19 08:48AM	Akari Therapeutics Announces Expanded Ophthalmology Program Based on Positive Emerging Data on LTB4-C5 Dual Action in Surface and Back of the Eye Diseases GlobeNewswire -10.97%
Apr-24-19 08:09AM	The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediciNova Benzinga
Apr-23-19 04:01PM	Akari Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights GlobeNewswire +15.82%
02:05PM	Positive News in The Biotech, Social Media, Financial & Cannabis Sectors Help the Market Towards New Highs ACCESSWIRE
11:04AM	Microcap Biotech Akari Rallies On Coversin Trial Results Benzinga
08:30AM	Akari Therapeutics Announces Positive Initial Phase II Clinical Data in Orphan Skin Disease Bullous Pemphigoid GlobeNewswire
Mar-27-19 04:15PM	Akari Therapeutics to Provide Update on its Eye Disease Program During Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting GlobeNewswire -5.00%
Mar-18-19 02:30PM	These Tech Stocks Could Test March Highs ACCESSWIRE +12.01%
Mar-14-19 10:06AM	What Kind Of Shareholders Own Akari Therapeutics, Plc (NASDAQ:AKTX)? Simply Wall St.
07:47AM	The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering Benzinga
Mar-13-19 02:35PM	These 4 Tech Stocks Are On The Rise On Wednesday (3/13/19) ACCESSWIRE +224.16%
10:35AM	Akari Therapeutics' stock rockets on massive volume after 'successful' pre-IND FDA meeting MarketWatch
08:30AM	Positive FDA Meeting Outlines Path Ahead for Akari Therapeuticss Coversin in Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) GlobeNewswire
Feb-21-19 08:30AM	Factors of Influence in 2019, Key Indicators and Opportunity within EnLink Midstream, Pepsico, Arista Networks, Maiden, GCI Liberty, and Akari Therapeutics New Research Emphasizes Economic Growth GlobeNewswire
Feb-04-19 12:45PM	Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up Zacks
Jan-29-19 11:10AM	Alexion's Ultomiris Meets Primary Endpoint in aHUS Study Zacks
Dec-26-18 11:19AM	What You Must Know About Akari Therapeutics, Plcs (NASDAQ:AKTX) Beta Value Simply Wall St.
Nov-30-18 04:05PM	Akari Therapeutics Announces New Data Highlighting Differentiation of Drug Candidate Coversin GlobeNewswire
Nov-15-18 09:00AM	Akari Announces Coversin Data to be Presented at 2018 Complement-Based Drug Development Summit GlobeNewswire
06:50AM	Akari Announces Third Quarter 2018 Financial Results and Business Highlights GlobeNewswire
Oct-25-18 08:55AM	Factors of Influence in 2018, Key Indicators and Opportunity within Intersect ENT, Akari Therapeutics, Ampio Pharmaceuticals, Virtusa, Umpqua, and Hamilton Lane New Research Emphasizes Economic Growth GlobeNewswire
Sep-30-18 07:30AM	Akari Therapeutics Announces New Clinical Data in Post-Transplant Thrombotic Microangiopathies. Data Supports Akaris Ongoing Clinical Expansion into a Range of Orphan Autoinflammatory Diseases That Are Either Mediated by Complement C5 or Have Synchronous LTB4 and C5 Activity GlobeNewswire
Sep-27-18 06:56AM	Akari Announces Second Quarter 2018 Financial Results and Business Highlights GlobeNewswire +11.97%
06:55AM	Akari Therapeutics Enters into a Securities Purchase Agreement for up to $20 Million with Aspire Capital Fund, LLC GlobeNewswire
Sep-25-18 07:00AM	Akari Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-12-18 07:00AM	Akari Therapeutics Announces New Preclinical Rheumatoid Arthritis Data and New Clinical Data in Patients with Bullous Pemphigoid, Highlighting Potential Advantages of Coversins bifunctional activity inhibiting both the Complement and Leukotriene Inflammatory Pathways GlobeNewswire +7.29%
Sep-04-18 08:30AM	Research Report Identifies Brady, Akari Therapeutics, MTGE Investment, Jones Lang LaSalle, New Relic, and Sorrento Therapeutics with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire +18.09%
Aug-20-18 09:00AM	The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Akari Therapeutics, plc -- AKTX GlobeNewswire
Aug-17-18 07:00AM	Akari Announces First Quarter 2018 Financial Results and Update on its Growing Pipeline of Phase II and Phase III Clinical Trials GlobeNewswire
Jun-15-18 08:00AM	Akari Therapeutics to Present Poster at the 23rd Congress of the European Hematology Association GlobeNewswire +8.99%
May-25-18 07:53PM	How Do Analysts See Akari Therapeutics Plc (NASDAQ:AKTX) Performing In The Years Ahead? Simply Wall St.
08:20AM	Market Trends Toward New Normal in Independent Bank, First Busey, American Public Education, The First Bancshares, Northfield, and Akari Therapeutics Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
May-21-18 08:00AM	Akari Therapeutics Receives Notice Related to Delay in 20-F Filing GlobeNewswire -6.84%
May-16-18 07:23PM	Should You Buy Akari Therapeutics Plc (NASDAQ:AKTX) Now? Simply Wall St.
Apr-16-18 07:20AM	Blog Exposure - Tetraphase Pharma Announced Data Presentations from IGNITE4 Study at 28th European Congress of Clinical Microbiology and Infectious Diseases ACCESSWIRE -5.74%
Apr-03-18 08:25AM	Analysis: Positioning to Benefit within ForeScout Technologies, CommerceHub, Newtek Business Services, Credit Acceptance, Akari Therapeutics, and Brady Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Mar-21-18 03:50PM	Edited Transcript of AKTX earnings conference call or presentation 21-Mar-18 12:30pm GMT Thomson Reuters StreetEvents

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead product candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barre syndrome, and atypical hemolytic uremic syndrome. Akari Therapeutics, Plc is based in London, the United Kingdom.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience